1. Home
  2. IART vs ZYME Comparison

IART vs ZYME Comparison

Compare IART & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IART
  • ZYME
  • Stock Information
  • Founded
  • IART 1989
  • ZYME 2003
  • Country
  • IART United States
  • ZYME United States
  • Employees
  • IART N/A
  • ZYME N/A
  • Industry
  • IART Medical/Dental Instruments
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • IART Health Care
  • ZYME Health Care
  • Exchange
  • IART Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • IART 1.2B
  • ZYME 1.2B
  • IPO Year
  • IART 1995
  • ZYME 2017
  • Fundamental
  • Price
  • IART $14.16
  • ZYME $19.66
  • Analyst Decision
  • IART Hold
  • ZYME Strong Buy
  • Analyst Count
  • IART 6
  • ZYME 9
  • Target Price
  • IART $15.40
  • ZYME $22.88
  • AVG Volume (30 Days)
  • IART 903.3K
  • ZYME 882.8K
  • Earning Date
  • IART 10-30-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • IART N/A
  • ZYME N/A
  • EPS Growth
  • IART N/A
  • ZYME N/A
  • EPS
  • IART N/A
  • ZYME N/A
  • Revenue
  • IART $1,621,738,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • IART $5.74
  • ZYME $99.52
  • Revenue Next Year
  • IART $4.35
  • ZYME N/A
  • P/E Ratio
  • IART N/A
  • ZYME N/A
  • Revenue Growth
  • IART 3.53
  • ZYME 95.94
  • 52 Week Low
  • IART $11.06
  • ZYME $9.03
  • 52 Week High
  • IART $27.13
  • ZYME $19.50
  • Technical
  • Relative Strength Index (RSI)
  • IART 43.83
  • ZYME 73.72
  • Support Level
  • IART $15.26
  • ZYME $17.27
  • Resistance Level
  • IART $16.42
  • ZYME $19.42
  • Average True Range (ATR)
  • IART 0.71
  • ZYME 0.77
  • MACD
  • IART -0.03
  • ZYME 0.08
  • Stochastic Oscillator
  • IART 28.55
  • ZYME 88.19

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: